Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

项目总结 幻觉。来自华盛顿大学参与者的参与者参与度和排序研究 参与和癌症基因组测序中心(WU-PE-CGS)将填补知识的关键空白， 研究不足的癌症人群的方法学和特征，导致最佳方法 基因组特征研究中的参与者参与、外展和交流。 进球了。WU-PE-CGS的总体目标是为直接方法建立一个严格的、科学的证据基础 癌症患者和治疗后癌症幸存者作为癌症研究参与者的参与。我们的 重点放在罕见和研究不足的癌症人群中，这些人群具有显著的差异，包括胆管癌， 多发性骨髓瘤和50岁以下的结直肠癌。参与者参与策略是最有效的 当它们与社区和患者合作在现实环境中进行调整和实施时 倡导利益相关者。 设置。我们的中心将位于一个特殊的环境中，以促进跨学科合作， 促进患者参与的新想法，并确保对患者参与和基因组的支持 在现实环境中为复杂的招聘和参与挑战找到解决方案的排序 代表不足的患者群体。来自华盛顿大学的重大匹配捐款将使 美国需要迅速和战略性地投资于创意。 目标。该中心的具体目标是：(1)推动参与者参与癌症研究领域 通过开展创新和有影响力的直接利益相关者参与， 持续评估和研究；(2)扩大一支由调查人员、患者和 倡导利益相关者；(3)通过了解障碍和提高能力来解决癌症差异 对于处于不利地位和研究不足的人群，可以遇到、使用和受益于基因组测序和 分析；(4)组织和整合中心单位，以促进我们中心内的跨学科、团队科学 以及整个PE-CGS网络。 创新和影响。WU-PE-CGS建立在两种癌症长期卓越的领导记录基础上 癌症连续体的差异和基因组研究。我们将特别创新，并允许 科学投资在几个方面都有显著的回报。首先，我们的中心具有鲜明的特点， 包括对癌症差异的综合关注，应用战略来增加参与者 参与研究，成功收购生物样品，以及出众的基因组测序专业知识。 其次，我们组建了一支多元化的世界级团队，与多个罕见和未被研究的项目建立了牢固的联系 癌症。第三，我们从不同的学科聘请研究人员，并投资于早期开发 职业学者。第四，我们将有战略地、创造性地传播产品，使其受益 研究人员、从业者和社区成员。第五，我们将与以患者为中心的卓越合作伙伴 和广泛的倡导团体，以吸引患者，优化招聘，并无缝返回结果。 来自这些群体、患者及其家人的意见是一种关键力量，将利用我们在 利益相关者参与的研究。最后，我们制定了一项有重点的战略，以实现 我们的部队。这些协同效应将使我们的中心成为最佳方法的国家资源 参与者在基因组特征研究和其他研究中的参与、推广和交流 随着技术的进步，这将加速科学界的进步，患者和他们的 社区。 总而言之，我们得天独厚地推进了参与者参与和排序网络 研究人员，整合与患者及其利益相关者的研究，建立智力资本，并显著 增强参与者参与和基因组特征研究的能力。该中心将 最终使卫生系统、提供者和罕见癌症患者受益，并导致癌症的减少 差距。

PROJECT SUMMARY Vision. Participant engagement and sequencing research from the Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS) will fill critical gaps in knowledge, methodology, and characterization of understudied cancer populations, leading to optimal approaches to participant engagement, outreach, and communication in genomic characterization studies. Goal. The overall goal of the WU-PE-CGS is to build a rigorous, scientific evidence base for approaches direct engagement of cancer patients and post-treatment cancer survivors as participants in cancer research. Our focus is on rare and understudied cancer populations with significant disparities including cholangiocarcinoma, multiple myeloma, and colorectal cancer under age 50. Participant engagement strategies are most effective when they are adapted and implemented in real-world settings in partnership with community and patient advocacy stakeholders. Setting. Our Center will be housed in an exceptional environment that fosters transdisciplinary collaboration, catalyzes new ideas in patient engagement, and ensures support for patient engagement and genome sequencing that finds solutions for complex recruitment and engagement challenges in real-world settings with underrepresented patient populations. Significant matching contributions from Washington University will allow us to quickly and strategically invest in ideas. Aims. The specific aims of the Center are to: (1) Advance the field of participant engagement to study cancer disparities and rare cancers by conducting innovative and impactful direct stakeholder engagement with continuous evaluation and research; (2) Expand an exceptional, diverse team of investigators, patients, and advocacy stakeholders; (3) Address cancer disparities by understanding barriers to and improving the ability for disadvantaged and understudied populations to encounter, use, and benefit from genomic sequencing and analysis; (4) Organize and integrate Center units to facilitate transdisciplinary, team science within our Center and across the PE-CGS Network. Innovations and impact. The WU-PE-CGS builds on a long and outstanding record of leadership in both cancer disparities and genomic research across the cancer continuum. We will be particularly innovative and allow for a significant return on the scientific investment in several ways. First, our Center has distinctive features that include a combined focus on cancer disparities, the application of strategies to increase participant engagement in research, success in biospecimen acquisition, and exceptional genomic sequencing expertise. Second, we have assembled a diverse, world class team with strong linkages to multiple rare and understudied cancers. Third, we engage investigators from different disciplines and invest in the development of early career scholars. Fourth, we will strategically and creatively disseminate products in ways that will benefit researchers, practitioners, and community members. Fifth, we will partner with exceptional patient-centered and wide-reaching advocacy groups to engage patients, optimize recruitment, and seamlessly return results. Input from these groups, patients, and their families is a key strength that will leverage our track record of stakeholder-engaged research. And finally, we have developed a focused strategy for collective integration of our units. These synergies will allow our Center to become a national resource for optimal approaches to participant engagement, outreach, and communication in genomic characterization studies and other studies as technologies advance that will accelerate progress for both the scientific community, patients and their communities. In summary, we are uniquely situated to advance a network of participant engagement and sequencing researchers, integrate research with patients and their stakeholders, build intellectual capital, and significantly enhance the capacity for participant engagement and genomic characterization studies. This Center will ultimately benefit health systems, providers, and people with rare cancers and lead to a reduction in cancer disparities.